MicroRNA‑23a acts as an oncogene in pancreatic carcinoma by targeting TFPI‑2

Wang,Wei; Ning,Jin‑Zhuo; Tang,Zhi‑Gang; He,Ying; Yao,Li-Chao; Ye,Lin; Wu,Lun

doi:10.3892/etm.2020.9181

MicroRNA‑23a acts as an oncogene in pancreatic carcinoma by targeting TFPI‑2

Authors:
- Wei Wang
- Jin‑Zhuo Ning
- Zhi‑Gang Tang
- Ying He
- Li-Chao Yao
- Lin Ye
- Lun Wu
View Affiliations

Affiliations: Department of Pancreatic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei 430079, P.R. China
Published online on: September 4, 2020 https://doi.org/10.3892/etm.2020.9181
Article Number: 53
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic carcinoma (PC) is a rapidly progressive, fatal malignant tumor with the poorest prognosis among all major carcinoma types. MicroRNAs (miRNAs/miRs) have been indicated to be key post‑transcriptional regulatory factors, which are involved in cancer development. The present study was designed to investigate the effect of miR‑23a on PC cell proliferation, metastasis and apoptosis. The expression of miR‑23a was detected in a normal pancreatic ductal epithelial cell line and three PC cell lines, and miR‑23a inhibitor or mimics were transfected into the Panc‑1 and MiaPaCa2 PC cells. The association between miR‑23a and tissue factor pathway inhibitor (TFPI)‑2 was examined using a luciferase reporter assay. MTT and flow cytometry assays were used to assess cell viability and apoptosis, respectively. Furthermore, wound‑healing, Transwell and Matrigel assays were used to evaluate cell migration and invasion abilities, and the protein expression level of TFPI‑2 was determined using western blot analysis. The results of the present study revealed that miR‑23a was upregulated in PC cells. Furthermore, TFPI‑2 was identified as a downstream target of miR‑23a, and TFPI‑2 expression was found to be increased following miR‑23a knockdown. In addition, functional assays revealed that downregulation of miR‑23a decreased PC cell proliferation, migration and invasiveness and promoted cell apoptosis, while miR‑23a overexpression exerted the opposite effects. Furthermore, TFPI‑2 knockdown rescued the biological effects on PC cells, which were induced by miR‑23a knockdown. The results of the present study indicated that miR‑23a negatively modulated TFPI‑2 expression in vitro and enhanced the malignant phenotypes of PC cells. Therefore, miR‑23a may be a potential marker and/or target for the diagnosis and treatment of PC.

View Figures

View References

1	Klein AP: Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 13:66–74. 2013.PubMed/NCBI View Article : Google Scholar
2	Kamisawa T, Wood LD, Itoi T and Takaori K: Pancreatic cancer. Lancet. 388:73–85. 2016.
3	Moutinho-Ribeiro P, Coelho R, Giovannini M and Macedo G: Pancreatic cancer screening: Still a delusion? Pancreatology. 17:754–765. 2017.PubMed/NCBI View Article : Google Scholar
4	Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 74:2913–2921. 2014.PubMed/NCBI View Article : Google Scholar
5	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
6	Talmadge JE and Fidler IJ: AACR centennial series: The biology of cancer metastasis: Historical perspective. Cancer Res. 70:5649–5669. 2010.PubMed/NCBI View Article : Google Scholar
7	Pang EJ, Yang R, Fu XB and Liu YF: Overexpression of long non-coding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumor Biol. 36:2403–2407. 2015.PubMed/NCBI View Article : Google Scholar
8	Li Y, Vandenboom TG II, Wang Z, Kong D, Ali S, Philip PA and Sarkar FH: miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res. 70:1486–1495. 2010.PubMed/NCBI View Article : Google Scholar
9	Kamisawa T, Isawa T, Koike M, Tsuruta K and Okamoto A: Hematogenous metastases of pancreatic ductal carcinoma. Pancreas. 11:345–349. 1995.PubMed/NCBI View Article : Google Scholar
10	Chaffer CL and Weinberg RA: A perspective on cancer cell metastasis. Science. 331:1559–1564. 2011.PubMed/NCBI View Article : Google Scholar
11	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004.PubMed/NCBI View Article : Google Scholar
12	Wu G, Li ZH, Jiang P, Zhang X, Xu YQ, Chen K and Li XW: MicroRNA-23a promotes pancreatic cancer metastasis by targeting epithelial splicing regulator protein 1. Oncotarget. 8:82854–82871. 2017.PubMed/NCBI View Article : Google Scholar
13	Zhang XJ, Jin Y, Song JL and Deng F: MiR-373 promotes proliferation and metastasis of oral squamous cell carcinoma by targeting SPOP. Eur Rev Med Pharmacol Sci. 23:5270–5276. 2019.PubMed/NCBI View Article : Google Scholar
14	Li Y, Zhang H, Dong Y, Fan Y, Li Y, Zhao C, Wang C, Liu J, Li X, Dong M, et al: MiR-146b-5p functions as a suppressor miRNA and prognosis predictor in non-small cell lung cancer. J Cancer. 8:1704–1716. 2017.PubMed/NCBI View Article : Google Scholar
15	Liu C, Jian M, Qi H and Mao WZ: MicroRNA-495 inhibits proliferation and metastasis and promotes apoptosis by targeting twist1 in gastric cancer cells. Oncol Res. 27:389–397. 2019.PubMed/NCBI View Article : Google Scholar
16	Qiao G, Li J, Wang J, Wang Z and Bian W: miR-381 functions as a tumor suppressor by targeting ETS1 in pancreatic cancer. Int J Mol Med. 44:593–607. 2019.PubMed/NCBI View Article : Google Scholar
17	Zhou Y, Li Z, Ding Y, Zhang P and Wang J: MicroRNA-340 suppresses pancreatic cancer growth by targeting BICD2. Pancreatology. 19:30556–30563. 2019.PubMed/NCBI View Article : Google Scholar
18	Yu H, Gao G, Cai J, Song H, Ma Z, Jin X, Ji W and Pan B: MiR-539 functions as a tumor suppressor in pancreatic cancer by targeting TWIST1. Exp Mol Pathol. 108:143–149. 2019.PubMed/NCBI View Article : Google Scholar
19	Su R, Dong L, Zou D, Zhao H, Ren Y, Li F, Yi P, Li L, Zhu Y, Ma Y, et al: MicroRNA-23a, -27a and -24 synergistically regulate JAK1/Stat3 cascade and serve as novel therapeutic targets in human acute erythroid leukemia. Oncogene. 35:6001–6014. 2016.PubMed/NCBI View Article : Google Scholar
20	Cai S, Chen R, Li X, Cai Y, Ye Z, Li S, Li J, Huang H, Peng S, Wang J, et al: Downregulation of microRNA-23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway. Oncotarget. 6:3904–3917. 2015.PubMed/NCBI View Article : Google Scholar
21	Wang G, Li B, Fu Y, He M, Wang J, Shen P and Bai L: miR-23a suppresses proliferation of osteosarcoma cells by targeting SATB1. Tumour Biol. 36:4715–4721. 2015.PubMed/NCBI View Article : Google Scholar
22	Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C and Croce CM: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 297:1901–1908. 2007.PubMed/NCBI View Article : Google Scholar
23	Diao H, Ye Z and Qin R: miR-23a acts as an oncogene in pancreatic carcinoma by targeting FOXP2. J Investig Med. 66:676–683. 2018.PubMed/NCBI View Article : Google Scholar
24	Liu N, Sun YY, Zhang XW, Chen S, Wang Y, Zhang ZX, Song SW, Qiu GB and Fu WN: Oncogenic miR-23a in pancreatic ductal adenocarcinogenesis via inhibiting APAF1. Dig Dis Sci. 60:2000–2008. 2015.PubMed/NCBI View Article : Google Scholar
25	Tang Z, Geng G, Huang Q, Xu G, Hu H, Chen J and Li J: Expression of tissue factor pathway inhibitor 2 in human pancreatic carcinoma and its effect on tumor growth, invasion, and migration in vitro and in vivo. J Surg Res. 167:62–69. 2011.PubMed/NCBI View Article : Google Scholar
26	Zhai LL, Wu Y, Huang DW and Tang ZG: Increased matrix metalloproteinase-2 and reduced tissue factor pathway inhibitor-2 expression correlate with angiogenesis and early postoperative recurrence of pancreatic carcinoma. Am J Transl Res. 7:2412–2422. 2015.PubMed/NCBI
27	Zhai LL, Wu Y, Cai CY and Tang ZG: Upregulated matrix metalloproteinase-2 and downregulated tissue factor pathway inhibitor-2 are risk factors for lymph node metastasis and perineural invasion in pancreatic carcinoma. Onco Targets Ther. 8:2827–2834. 2015.PubMed/NCBI View Article : Google Scholar
28	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2012.
29	Hussain H and Chong NF: Combined overlap extension PCR method for improved site directed mutagenesis. Biomed Res Int. 2016(8041532)2016.PubMed/NCBI View Article : Google Scholar
30	Meng H, Huang Q, Zhang X, Huang J, Shen R and Zhang B: MiR-449a regulates the cell migration and invasion of human non-small cell lung carcinoma by targeting ADAM10. Onco Targets Ther. 12:3829–3838. 2019.PubMed/NCBI View Article : Google Scholar
31	Tao C, Sun H, Sang W and Li S: miRNA-99a inhibits cell invasion and migration in liver cancer by directly targeting HOXA1. Oncol Lett. 17:5108–5114. 2019.PubMed/NCBI View Article : Google Scholar
32	Pan DS, Cao P, Li JJ, Fan D and Song ZQ: MicroRNA-374b inhibits migration and invasion of glioma cells by targeting EGFR. Eur Rev Med Pharmacol Sci. 23:4254–4263. 2019.PubMed/NCBI View Article : Google Scholar
33	Zhu LH, Liu T, Tang H, Tian RQ, Su C, Liu M and Li X: MicroRNA-23a promotes the growth of gastric adenocarcinoma cell line MGC803 and downregulates interleukin-6 receptor. FEBS J. 277:3726–3734. 2010.PubMed/NCBI View Article : Google Scholar
34	Wang Z, Wei W and Sarkar FH: miR-23a, a critical regulator of ‘migR’ation and metastasis in colorectal cancer. Cancer Discov. 2:489–491. 2012.PubMed/NCBI View Article : Google Scholar
35	Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, Yao X, Pan Z, Zhang P, Li J, et al: Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer. 123:972–978. 2008.PubMed/NCBI View Article : Google Scholar
36	He Y, Meng C, Shao Z, Wang H and Yang S: MiR-23a functions as a tumor suppressor in osteosarcoma. Cell Physiol Biochem. 34:1485–1496. 2014.PubMed/NCBI View Article : Google Scholar
37	Lu S and Xu Q: MicroRNA-23a inhibits melanoma cell proliferation, migration, and invasion in mice through a negative feedback regulation of SDCBP and the MAPK/ERK signaling pathway. IUBMB Life. 71:587–600. 2019.PubMed/NCBI View Article : Google Scholar
38	Eble JA and Niland S: The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis. 36:171–198. 2019.PubMed/NCBI View Article : Google Scholar
39	Chang TT, Thakar D and Weaver VM: Force-dependent breaching of the basement membrane. Matrix Biol. 57-58:178–189. 2017.PubMed/NCBI View Article : Google Scholar
40	Wang G, Zeng Y, Chen S, Li D, Li W, Zhou Y, Singer RH and Gu W: Localization of TFPI-2 in the nucleus modulates MMP-2 gene expression in breast cancer cells. Sci Rep. 7(13575)2017.PubMed/NCBI View Article : Google Scholar
41	Konduri SD, Tasiou A, Chandrasekar N, Nicolson GL and Rao JS: Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis. 18:303–308. 2000.PubMed/NCBI View Article : Google Scholar
42	Iochmann S, Bléchet C, Chabot V, Saulnier A, Amini A, Gaud G, Gruel Y and Reverdiau P: Transient RNA silencing of tissue factor pathway inhibitor-2 modulates lung cancer cell invasion. Clin Exp Metastasis. 26:457–467. 2009.PubMed/NCBI View Article : Google Scholar
43	Ma S, Chan YP, Kwan PS, Lee TK, Yan M, Tang KH, Ling MT, Vielkind JR, Guan XY and Chan KW: MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 71:583–592. 2011.PubMed/NCBI View Article : Google Scholar
44	Andresen MS, Stavik B, Sletten M, Tinholt M, Sandset PM, Iversen N and Skretting G: Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells. Sci Rep. 10(4036)2020.PubMed/NCBI View Article : Google Scholar
45	Chen B, Zhu A, Tian L, Xin Y, Liu X, Peng Y, Zhang J, Miao Y and Wei J: miR 23a suppresses pancreatic cancer cell progression by inhibiting PLK 1 expression. Mol Med Rep. 18:105–112. 2018.PubMed/NCBI View Article : Google Scholar